Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...

On May 20, 2024, Teva Pharmaceuticals (“Teva”) and Alvotech announced the availability of SIMLANDI (adalimumab-ryvk) injection in the United States, for the treatment of adult rheumatoid arthritis, ...

NORTH CHICAGO, Ill., Sept. 10, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® ...

One biologic, adalimumab, is currently approved to treat hidradenitis suppurativa. Adalimumab works by targeting a specific inflammation pathway involved in the condition. Hidradenitis suppurativa (HS ...

RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today a ...

SAN FRANCISCO, U.S. and SUZHOU, China, Sept. 3, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

Combined treatment with adalimumab and methotrexate effectively treats long-standing rheumatoid arthritis about five times better than methotrexate alone, a new Cochrane review shows. Federico Navarro ...

Please provide your email address to receive an email when new articles are posted on . Etanercept and adalimumab are both impactful at improving the health of ...

Little is known about the effect of specific anti–interleukin-23 therapy, as compared with established anti–tumor necrosis factor therapies, for the treatment of moderate-to-severe plaque psoriasis.